Delving into the Latest Updates on Enterovirus type 71 vaccine(Beijing Luzhu Biopharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Enterovirus 71 infectionHand, Foot and Mouth Disease

Inactive Indication-

Originator Organization

Beijing Luzhu Biopharmaceutical Co., Ltd.

Active Organization

Beijing Luzhu Biopharmaceutical Co., Ltd.

Beijing Lüzhu Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDVaccination has been proven effective against infection with enterovirus A71 (EV-A71) in clinical trials, but vaccine effectiveness in real-world situations remains incompletely understood. Furthermore, it is not clear whether previous vaccination will result in symptom attenuation among post-vaccinated cases.METHODSBased on long-term data extracted from the only designed referral hospital for infectious diseases, we used a test-negative case-control design and multivariate logistic regression models to analyze the effectiveness of EV-A71 vaccine against hand, foot and mouth disease (HFMD). And then, generalized linear regression models were used to evaluate the associations between prior vaccination and disease profiles.RESULTSWe selected 4883 inpatients for vaccine efficacy estimations and 2188 inpatients for disease profile comparisons. Vaccine effectiveness against EV-A71-induced HFMD for complete vaccination was 63.4 % and 51.7 % for partial vaccination. The vaccine effectiveness was higher among cases received the first dose within 12 months. No protection was observed against coxsackievirus (CV) A6-, CV-A10- or CV-A16-associated HFMD among children regardless of vaccination status. Completely vaccinated cases had shorter hospital stay and disease course compared to unvaccinated cases (P < 0.05).CONCLUSIONSThese findings reiterate the need to continue the development of a multivalent vaccine or combined vaccines, and have implications for introducing optimized vaccination strategies.

01 Aug 2011·VaccineQ3 · MEDICINE

Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys

Q3 · MEDICINE

Article

Author: Longding Liu ; Jingjing Wang ; Yun Liao ; Chenghong Dong ; Lichun Wang ; Xuemei Zhang ; Qihan Li ; Yan Liang ; Ruixiong Na ; Hongling Zhao

A number of commonly recognized public health issues are associated with EV71 infection, including the induction of severe cases of hand-foot-and-mouth disease (HFMD). Because of such issues, research and development of EV71 vaccine candidates is of growing importance. In the present study, an experimental EV71 inactivated vaccine was prepared, and its corresponding immunogenicity was analyzed. The immune responses and immunoprotective effect induced by the vaccine in mice and rhesus monkeys are described, and the two animal models are compared to evaluate the potential of assessing the inactivated vaccine's immunogenicity in these two species. In addition to assessing the vaccine's efficacy in mice, our data further elucidate the significance and value of assessing the immunogenicity and immunoprotection of vaccine candidates in rhesus monkeys by relying on a range of analyses, including pathological, etiological and lethal challenge analyses.

100 Deals associated with Enterovirus type 71 vaccine(Beijing Luzhu Biopharmaceutical)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enterovirus 71 infection	Phase 2	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	19 Oct 2021
Enterovirus 71 infection	Phase 2	CN	Beijing Lüzhu Biotechnology Co., Ltd.	19 Oct 2021
Hand, Foot and Mouth Disease	Phase 2	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	19 Oct 2021
Hand, Foot and Mouth Disease	Phase 2	CN	Beijing Lüzhu Biotechnology Co., Ltd.	19 Oct 2021